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IgG‑antibodies display differentially 
restricted igG subclass distribution
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Antibodies against several self‑glycans on glycosphingolipids are frequently detected in different 
neurological disorders. Their pathogenic role is profusely documented, but the keys for their origin 
remain elusive. Additionally, antibodies recognizing non‑self glycans appear in normal human serum 
during immune response to bacteria. Using HPTLC‑immunostaining we aimed to characterize IgM 
and IgG subclass antibody responses against glycosphingolipids carrying self glycans (GM1/GM2/GM3/
GD1a/GD1b/GD3/GT1b/GQ1b) and non‑self glycans (Forssman/GA1/“A” blood group/Nt7) in sera from 
27 randomly selected neurological disorder patients presenting IgG reactivity towards any of these 
antigens. Presence of IgG2 (p = 0.0001) and IgG1 (p = 0.0078) was more frequent for IgG antibodies 
against non‑self glycans, along with less restricted antibody response (two or more simultaneous IgG 
subclasses). Contrariwise, IgG subclass distribution against self glycans showed clear dominance for 
IgG3 presence (p = 0.0017) and more restricted IgG‑subclass distributions (i.e. a single IgG subclass, 
p = 0.0133). Interestingly, anti‑self glycan IgG antibodies with simultaneous IgM presence had higher 
proportion of IgG2 (p = 0.0295). IgG subclass frequencies were skewed towards IgG1 (p = 0.0266) 
for “anti‑self glycan A” subgroup (GM2/GM1/GD1b) and to IgG3 (p = 0.0007) for “anti‑self glycan B” 
subgroup (GM3/GD1a/GD3/GT1b/GQ1b). Variations in players and/or antigenic presentation pathways 
supporting isotype (M‑G) and IgG‑subclass pattern differences in the humoral immune response 
against glycosphingolipids carrying non‑self versus self‑glycans are discussed.
Abbreviations
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Human sera commonly display anti-glycan antibodies (i.e. antibodies recognizing saccharide sequences on one 
or more types of glycoconjugates, regardless of the inducer immunogen)1. Certain membrane lipids (known as 
glycosphingolipids) exhibit oligosaccharides as their hydrophilic head groups, granting access for binding by 
viruses, toxins and  antibodies2. Normal subjects routinely display naturally-occurring antibodies recognizing 
non-self glycosphingolipids: archetypal examples are the ABO blood group agglutinins, arisen when blood group 
“0” individuals develop antibodies able to agglutinate blood group “A”/“B” red blood  cells3. These antibodies 
appear within the context of a normal immune response against bacteria colonizing intestinal or respiratory 
 tract4. Our laboratory described a similar origin for IgM antibodies recognizing a few self glycosphingolipids 
such as gangliosides GM1 and  GD1b5; however, these low affinity, cross-reactive IgM are non-pathogenic (normal 
anti-GM1 IgM  antibodies6). On the contrary, autoimmune diseases frequently exhibit immune reactivity towards 
self-glycosphingolipids7. In particular, gangliosides (glycosphingolipids abundantly found in nervous system) 
are often targeted by antibodies present in a variety of neurological  diseases8. Multiple triggering mechanisms 
for nervous system dysfunction elicited by anti-ganglioside antibodies have been well documented: formation 
of a membrane attack complex (MAC) at motor nerve terminals by complement activation on the nerve cell 
membrane, impairment of axonal membrane properties at the nodes of Ranvier causing disfunction of voltage-
gated sodium channels (Nav) and conduction block; induction of apoptotic cascade activation in dorsal root 
ganglion cells; blockade of neurotransmitter release at motor nerve terminals by presynaptic inhibitory effect 
on voltage-gated Ca channel currents; complement-independent function alteration of certain receptors at lipid 
rafts acting as signaling platforms; and so  forth9. Remarkably, the origin of anti-ganglioside antibodies is much 
less clear. Molecular mimicry between lipopolysaccharides from specific Campylobacter jejuni serotypes and 
ganglioside structures can either cause Guillain Barré syndrome (by inducing anti-GM1 and anti-GD1a anti-
bodies) or Miller-Fisher syndrome (by inducing anti-GQ1b antibodies)10–12. Intriguingly, only a small fraction 
of individuals develops further neuropathy after infection with proper C. jejuni serotypes, implying additional 
bacterial or host  constraints13,14. For anti-GM1 antibodies, we have proposed this additional requirement to be 
randomly elicited mutations affecting the binding site of normal anti-GM1 IgM antibodies (“binding site drift” 
hypothesis)15. Altogether, “molecular mimicry” and “binding site drift” hypotheses complement each other to 
depict how neuropathy-associated IgM and IgG anti-GM1 antibodies  originate16.
Although recent work on IgM and IgG isotypes has extended this view to explain the origin of other anti-self 
glycosphingolipid antibodies associated with neurological  disorders17, some questions persist. These types of IgG 
antibodies are absent in healthy  humans6,17. Polysaccharides, some other nonprotein antigens (e.g. glycosphin-
golipids), and few proteins (e.g. flagellin) are regarded as T-cell independent (TI) antigens: i.e. they are able to 
activate B-1b and splenic marginal zone (MZ) B cells without intracellular processing and lacking assistance 
from CD4 + T helper (Th)  cells18. B-1b or splenic MZ B cells exposed to cytokines such as B-cell activating fac-
tor (BAFF) and a proliferation-inducing ligand (APRIL)—generated mostly by dendritic cells—can undergo 
antibody class  switching19. In contrast, most proteins are internalized by antigen-presenting cells (B-2 cells, 
macrophages, and dendritic cells), digested into peptide fragments and combined with MHC-class molecules to 
form MHC-peptide complexes that are displayed on the surface of the antigen-presenting cells to be recognized 
by Th-cell receptors (TCR). The specific recognition activates the B-2 cells (linked recognition), inducing anti-
body production and class switching. Human IgG isotype response is in turn divided into four subclasses (1 to 
4) with different heavy chains influencing their own properties (e.g. Fc receptor affinity) and biological functions 
(e.g. complement system activation ability)20. Total IgG subclass levels in autoimmune disease patients do not 
differ substantially from those measured in healthy individuals; however, certain specific antibodies can exhibit 
variable subclass  restrictions21–23. Generally speaking, IgG1 and IgG3 subclasses are mainly elicited against pro-
tein antigens, whereas certain glycan antigens preferentially induce IgG2  responses24. While antigen nature can 
have an impact on the type of IgG subclass  elicited25, IgG subclass can also depend on the type of T helper cell 
(Th)  response26. Th1 cells produce interferon-gamma (IFN-γ) and interleukin (IL) 2,Th2 cells produce IL-4 and 
IL-527, and Th17 cells produce IL-17, IL-21, and IL-2228. Nevertheless, distinction between Th1, -2 and -17 cells 
is less pronounced in humans than in experimental mouse  models29. Prior studies on neuropathy-associated 
anti-GM1, anti-GD1a and anti-GQ1b IgG antibodies indicate predominance for IgG1, IgG3 or  both30–33; however, 
these studies lacked simultaneous evaluation of subclass distribution against non-self glycans for comparison 
purposes. In the present work, we assessed IgG-subclass humoral immune response against various self and 
non-self glycan-carrying glycosphingolipids in patients with diverse neurological disorders. Reactivity pattern 
differences were thoroughly analyzed in the context of potential origin diversity for these antibodies.
Results
IgG antibody subclass distribution is different between responses against self glycan‑ and 
non‑self glycan‑carrying glycosphingolipids. We comparatively analyzed the percentage distribution 
for anti-non-self glycan and anti-self glycan IgG-subclass antibodies in 27 randomly selected patient serum 
samples (positive for diverse anti-self glycan IgG antibodies) by HPTLC-I. Figure 1A shows patient # 11 serum 
analysis as an example: anti-non-self glycan reactivity comprised anti-Forssman antibodies (IgM), anti-“A” gly-
cosphingolipid antibodies (IgM), anti-Nt7 antibodies (IgM, IgG1 and IgG2), and anti-GA1 antibodies (IgM). 
Anti-self glycan reactivity was formed by anti-GM2 (IgM), anti-GM1 (IgM and IgG1) and anti-GD1b (IgM 
and IgG1) antibodies. These analyses were repeated for all patient serum samples evaluated (see Supplementary 
Figure S1). Figure 1B summarizes the different distributions of anti-self and anti-non self-glycan IgG-subclass 
antibodies for each neurological disorder patient. When necessary, inhibition experiments using soluble self 
glycan-carrying glycosphingolipids were performed to confirm or discard differences in IgM and IgG fine spe-
cificities (results not shown). Initial evaluation of HPTLC-I results indicated the observed patterns of anti-self 
glycan IgG antibodies correlated with the specific diseases for some of the neurological disorders most repre-
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sented in our samples: IgG anti-GM1 in Guillain Barré syndrome (7 of 8; 88%) and IgG anti-GQ1b in Miller 
Fisher syndrome (3 of 4; 75%)8.
For IgG subclass distribution analyses of each given antigen group, we plotted the percentage of serum sam-
ples positive for each IgG subclass (considering the number of samples positive for any IgG subclass towards 
that antigen as the 100%; see Materials and Methods). Anti-non self glycan IgG antibodies had a significantly 
higher frequency of IgG1 (p = 0.0078) and IgG2 (p = 0.0001). In contrast, sera positive for anti-self glycan IgG 
antibodies showed a more frequent presence of IgG3 (p = 0.0017; Fig. 2).
Examined in close detail across the different serum samples, some IgG antibody responses comprised two 
or more different IgG subclasses, whereas others were formed by a single IgG subclass. The reactivity against 
self glycans was significantly associated to the presence of a single IgG subclass (p = 0.0133), thus representing a 
more restricted antibody response compared to that towards non-self glycans (Fig. 3).
Figure 1.  Distribution of anti-non-self glycan and anti-self glycan IgM and IgG subclass antibodies in 
neurological disorder patients. (A) A representative HPTLC-I result, corresponding to patient # 11. After serum 
incubation, proper specific secondary antibody (see M&M) for binding detection of each isotype (IgM or 
IgG) or each IgG subclass (IgG1, IgG2, IgG3 or IgG4) was added. On left plate the different glycosphingolipids 
were visualized with orcinol reagent. (B) Summary of anti-non-self glycan and anti-self glycan IgM and IgG 
subclasses found in 27 randomly chosen, anti-self glycan IgG Ab-positive, neurological disorder patients. 
Presence (yellow squares) or absence (blue squares) of IgM and IgG antibody subclasses reactive for each 
glycosphingolipid (by HPTLC-I) is shown. Patient number (Patient #) and neurological disorder diagnosis (Dx) 
are detailed in far-left columns. ALS amyotrophic lateral sclerosis, AMN asymmetric motor neuropathy, CIDP 
chronic inflammatory demyelinating polyneuropathy, DN diabetic neuropathy, GBS Guillain-Barré syndrome, 
LMND lower motor neuron disease, MFS Miller Fisher syndrome, MMN multifocal motor neuropathy, PNS 
paraneoplastic syndrome, SMN sensory-motor neuropathy.
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Changes in IgG antibody subclass distribution within responses against different self gly‑
can‑carrying glycosphingolipids. IgM populations recognizing certain self glycan-carrying glycosphin-
golipids (GM2/GM1/GD1b) have been reported in normal human  sera6, leaving room for potential antibody 
response differences within the various self glycan glycosphingolipids tested. Based on this, reactivities against 
anti-self glycan glycosphingolipids were subgrouped in “anti-self glycan A” (GM2/GM1/GD1b) and “anti-self 
glycan B” (GD3/GQ1b/GD1a/GM3/GT1b, see “Methods”). The proportion of IgG1 subclass antibody response 
was significantly higher for anti-self glycan A than for anti-self glycan B subgroup (p = 0.0266). On the contrary, 
anti-self glycan B subgroup reached a significantly higher IgG3 proportion compared to anti-self glycan A sub-
group (p = 0.0007; Fig. 4), supporting the notion for a distinct type of IgG response within the antibodies against 
self glycans.
The presence of anti‑self glycan IgM antibody counterpart is associated with differences in 
anti‑self glycan igG antibody subclasses. Irrespective of their specificity, some populations of anti-
self glycan IgG antibodies were present along with their IgM counterpart, while others had their IgM coun-
terpart absent (Fig. 1B). We therefore grouped anti-self glycan IgG antibody subclass results in different anti-
body subpopulations based on the simultaneous presence or absence of IgM counterpart. Anti-self glycan IgG 
responses present along with their IgM counterpart displayed a higher proportion of IgG2 compared to those 
IgG responses without IgM counterpart (p = 0.0295; Fig. 5).
Figure 2.  Anti-self glycan antibodies have a different IgG subclass distribution compared to those against non-
self glycans. Percentage of samples having antibody reactivity against antigens grouped in non-self glycan (blue 
bars) and self glycan (red bars) are shown for each IgG subclass. The different anti-non-self glycan and anti-self 
glycan IgG subclass antibody reactivities were determined using HPTLC-I (**: p < 0.01; ***:p < 0.001; Fisher’s 
exact test).
Figure 3.  The reactivity against self glycans is associated to a more restricted IgG subclass antibody response. 
Stacked bars show proportion of IgG antibody populations composed by single (“one”) versus multiple different 
(“two”, “three” or “four”) IgG subclasses in anti-non-self glycan and anti-self glycan IgG antibody responses. The 
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Discussion
Even though invertebrates can distinguish self- from non-self components, it is not until the level of terrestrial 
vertebrates—amphibians, reptiles, birds, and mammals—that a complete immune system with thymus, spleen, 
bone marrow, and lymph nodes is present and IgM and IgG antibodies are  made34. Besides their crucial role in 
host defense and homeostasis, improper control of antibody production can generate antibodies towards certain 
self-antigens (such as glycan antigens) and cause autoimmune  diseases8. The structural similarities between 
non-self and self glycans could indicate connections between both  responses16. In the present work, we char-
acterized the antibody immune response (IgM, total IgG and IgG subclasses) against diverse non-self and self 
glycosphingolipids in a cohort of patients with neurological disorders. Parallel evaluation of the humoral immune 
response against glycosphingolipids carrying either non-self glycans or self glycans allowed comparisons between 
both types of responses, where anti-non-self glycan IgM antibodies are considered anti-bacterial  antibodies4,5,35.
As already observed, anti-non-self glycan IgG antibodies always had their IgM  counterpart17, and presented 
a less restricted IgG subclass response (i.e. two or more different IgG subclasses). Displaying IgG2 and IgG1 as 
prevailing IgG subclasses, they resembled antibody responses against bacterial  glycans36,37, with IgG2 hinting at a 
relevant contribution of a TI immune response to these antibody  populations38. On the contrary, IgG antibodies 
against self glycans frequently exhibited a more restricted IgG-subclass distribution (i.e. a single IgG subclass) 
and an increased proportion of IgG3 subclass (consistent with a T-cell dependent (TD) immune  response39.
With different biological features, three subsets of naïve B cells craft normal antibody repertoire populations 
after differentiation into plasma cells: B-1 B cells (typically subdivided into B-1a and B-1b B cells), follicular (FO) 
B cells, and MZ B  cells40. B-1 B cells (residing mainly in the peritoneal and pleural cavities) produce IgM anti-
bodies directed against T-independent (TI) antigens like carbohydrate or phospholipid  antigens41. FO and MZ 
Figure 4.  The IgG subclass frequencies are skewed towards different IgG subclasses between anti-self glycan 
A and anti-self glycan B responses. IgG subclass frequency distributions for antigens grouped in self glycan 
A (peach bars) and self glycan B (purple bars) are shown. Antibody reactivities from each subclass were 
determined using HPTLC-I. (**: p < 0.01; ***: p < 0.001; Fisher’s exact test).
Figure 5.  IgM counterpart presence for anti-self glycan IgG antibody responses is associated with an increased 
frequency of IgG2 subclass. Antibody reactivities of anti-self glycan antibodies detected along with IgM (striped 
bars) versus anti-self glycan antibodies without IgM counterpart (red-filled bars) were determined for each 
subclass using HPTLC-I. *: p < 0.05 (Fisher’s exact test).
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B cells (often referred to as B-2 cells) are present in secondary lymphoid organs. Although both B-2 populations 
can experience Ig class switching and differentiate into memory  cells40,42, FO B cells are primarily responsible for 
generating long-lasting, high affinity IgG antibodies against T-dependent  antigens40, while MZ B cells can also 
recognize TI carbohydrate and phospholipid antigens (like B-1 cells do)42. TI type II immune responses gener-
ate memory B  cells43. IgM-expressing memory B cells with  IgM+IgD+CD27+ phenotype can undergo secondary 
germinal center reactions upon reactivation with glycan antigens, differentiate to plasma cells and switch their 
isotype to  IgG244,45. We observed significantly more IgG2 contribution when IgM was present in anti-self glycan 
responses. IgG2 has lower ability to activate complement, to induce antibody-dependent cell-mediated cytotox-
icity and to trigger antibody-dependent cellular phagocytosis than IgG1 and  IgG320: competition of IgG2 with 
other IgG subclasses for antigen binding in a context of IgG2 anti-self glycan relative enrichment could lead to 
lessen pathogenic events, and to an overall reduced severity of the neurological disorder.
Glycan-antibody interactions occur via a number of attractive forces of hydrophilic and hydrophobic  nature46: 
the acquisition, modification or loss of interaction points allows emergence of clones with specificity changes. 
Successive B-cell activation events introducing single nucleotide changes at high speed (~ 1 mutation every  103 
base pairs/generation) can provide fast BCR  diversification47 and some variants with potential affinity maturation 
through somatic  hypermutation48. In the context of a process we have coined as “binding site drift”  hypothesis16, 
new specificities could now lead these anti-non self glycan antibodies to cross-react with sequences similar to 
those from self glycan. Bacterial-driven B-cell activations can expand these anti-self glycan IgG B-cell clones. 
Upon reaching a certain antibody affinity threshold value, these B-cell clones can now be activated by self glycan 
oligosaccharide structures, either on self molecules or on foreign components from certain microorganisms (e.g. 
Campylobacter jejuni LPS O-antigen with oligosaccharide motifs similar to GM1, GD1a, GD3, GT1a, GQ1b; 
Haemophilus influenzae mimicking GM1 and GT1a; Cytomegalovirus resembling  GM28). Even though glycans are 
considered TI antigens, our findings regarding IgG subclasses suggest anti-self glycan responses can develop by 
two mechanisms: one TI (for anti-self glycan with IgM counterpart) and the other TD (for both types of anti-self 
glycan). T-cell involvement is indeed a likely event: MZ B cells can present lipoglycans and glycosphingolipids to 
CD1-restricted α/β and γ/δ T-cells. Activation via CD40L–CD40 and T cell multiplication provide the context 
for proliferation and antibody responses with eventual class  switch49. That would not necessarily be detrimental 
for IgM: IgG antibody responses from MZ B-cells tend to maintain IgM production, even for long-term memory 
B-cell  populations50.
How do anti-self glycan IgG antibodies occur if they have no IgM counterpart in normal human serum? One 
possibility would be a response against self glycan initiated by anti-self glycan (autoreactive) B-cells with surface 
IgM, leaving only anti-self glycan memory B-cells carrying surface IgG remaining after this first response. We 
hypothesize anti-self glycan  IgM+ B-cell clones populations that experienced a “binding site drift” process and 
are activated by self glycan would have the chance to expand. Some selected B-cell clones could then change 
their isotype to some of the different IgG subclasses, overall resulting in two or more IgG subclasses elicited in 
addition to IgM. On the contrary, clones originated from a “binding site drift” event at the IgG level are already 
committed to an IgG subclass. Therefore, expansion of one of those clones would generate only anti-self glycan 
antibodies from that specific IgG subclass, with neither anti-self glycan IgM antibodies nor the remaining IgG 
subclasses. This could account for the less restricted IgG subclass distribution observed for anti-non-self glycan 
IgG antibodies, compared to anti-self glycan IgG antibodies. Implying a potential association between IgM pres-
ence, a broader IgG subclass response and a substantial TI component, these and the aforementioned findings 
are represented in Fig. 6.
Within anti-self glycan IgG antibody reactivity (showing increased IgG3 subclass proportion, i.e. TD 
response), antibodies recognizing “self glycan B” subgroup had significantly higher proportion of IgG3 than 
those against “self glycan A” subgroup, suggesting origin differences. It is important to note that the “self glycan B” 
subgroup (GM3/GD3/GD1a/GT1b/GQ1b) comprises glycosphingolipids carrying a N-Acetyl Neuraminic Acid 
(NeuNAc) bound to a terminal galactose (NeuNAcα2,3Gal). This is a very important factor regarding anti-self 
glycan antibody specificity: for example, antibodies towards  GM1 (part of “self glycan A” subgroup) require a free 
terminal galactose and (in some patients) an internal NeuNAc for binding, rendering them unable to cross-react 
with self glycans carrying terminal NeuNAc (“self glycan B”). The inbalance in IgG1-/IgG3-subclass proportion 
could have consequences in pathology development, since IgG3-subclass has a better complement activator 
ability than  IgG125 albeit its three-times shorter plasma half-life 20. Considering antibodies against terminal 
NeuNAcα2,3Gal epitope have been preferentially associated with axonal  damage51, one can speculate that the 
higher biological activity of IgG3 can have an influence on the greater severity and slower recovery observed in 
the axonal forms (compared to demyelinating variants) of Guillain-Barré  syndrome52.
Anti-self glycan antibodies are an important component in the multifactorial process defining clinical evo-
lution for certain neurological disorders. Evidence from GBS patients with anti-GM1 IgG antibodies indicates 
they do not present too many different populations simultaneously, although different patients exhibit differ-
ent anti-GM1 antibody fine  specificities53. We could consider they together represent different possibilities of 
antibody specificity changes and expand this perspective to other anti-self glycan IgG-mediated neurological 
disorders, assuming that emergence of different anti-self glycan IgG antibody populations results from a random 
process. As we discussed earlier, in the context of the “binding site drift” hypothesis we could potentially foresee 
different types of antibody responses for the same self glycan target. One response, originated from an anti-
self glycan  IgM+ B-cell population that drifted and is now activated by self glycan can lead to some IgM clones 
changing their isotype to produce various different IgG subclasses in combinations of TI responses (mainly 
IgG2) and TD responses (mainly IgG1 and IgG3). In contrast, a response generated from anti-self glycan  IgG+ 
B-cell clones (already committed to a determined IgG subclass) that drifted at the IgG level (upon expansion of 
one of those clones in a TD response) would make only that specific IgG subclass. Based on biological activity 
disparities exhibited by each IgG subclass, the differences in IgG subclass responses generated could have clinical 
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implications concerning disease severity, response to therapies and/or recovery time, as it has been observed for 
the slower recovery in GBS associated with anti-GM1 IgG1  antibodies32. Further research is warranted exploring 
the influence that different types of IgG subclass responses against self glycan-carrying glycosphingolipids could 
have in clinical evolution of other autoimmune neurological disorders.
Methods
Human sera. Disease serum samples were collected before any immune treatment from patients attending 
Neurology services from Hospital “Ramos Mejía” and Hospital Nacional de Clínicas “José de San Martín” (Bue-
nos Aires, Argentina) with early symptoms of neurological disease. After clot separation, sera were submitted to 
our laboratory for routine determination of anti-glycosphingolipid antibodies (GM1, GM2, GM3, GD1a, GD1b, 
GD3, GT1b, GQ1b). From samples resulting positive for IgG antibodies against any of these self glycan-carrying 
glycosphingolipids, we randomly selected 27 patients for further analysis (amyotrophic lateral sclerosis, n = 2; 
asymmetric motor neuropathy, n = 2, chronic inflammatory demyelinating polyneuropathy, n = 1, diabetic neu-
ropathy, n = 1; Guillain-Barré syndrome, n = 8; lower motor neuron disease, n = 2; Miller Fisher syndrome, n = 4; 
multifocal motor neuropathy, n = 1; paraneoplastic syndrome, n = 1; sensory-motor neuropathy, n = 5). With dif-
ferent extents, all these neurological disorders have been reported to present autoimmune  components8,54,55. All 
procedures were performed in accordance with Ethical Guidelines on Research Involving Human  Subjects56 and 
with ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments, with prior 
approval by the Ethics Committee of CIQUIBIC-CONICET. Informed consent was obtained from the patients.
Figure 6.  IgG antibody subclass responses are qualitatively different between self glycans and non-self glycans. 
Trends are displayed proportionally to percentage distributions for each isotype and subclass. TI T-independent 
antibody response, TD T-dependent antibody response.
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Glycosphingolipids. Glycosphingolipids were obtained from the following biological materials: Sandhoff 
disease human brain for GM2; dog erythrocytes for GM3; chick brain for GD3; human brain for GM1, GD1a, 
GD1b, GT1b, and GQ1b; sheep erythrocytes for Forssman glycosphingolipid (Forssman); human blood group 
"A” meconium for blood group "A" glycosphingolipid; Calliphora vicina pupae for Nt7  glycosphingolipid57. 
Folch upper phase from partitioned lipid  extract58 was sequentially purified using DEAE -chromatography59 
and HPLC on Iatrobeads silica-gel  column60. Acid hydrolysis of cow brain gangliosides was used to prepare 
asialo-GM1 (GA1)61. Lipid purity was checked by HPTLC with orcinol reagent.
High performance thin layer chromatography (HPTLC)‑immunostaining. HPTLC with subse-
quent immunodetection (HPTLC-I) represents the “golden standard” to detect anti-glycosphingolipid antibod-
ies and confirm autoreactivity  results62,63. Using a tank designed to obtain highly reproducible  chromatograms64, 
glycosphingolipids (0.3 nmoles each) were resolved on HPTLC plates in the running solvent chloroform–meth-
anol-aqueous 0.2%  CaCl2 (45:45:10). Plates were air-dryed and coated by dipping for 2 min in a 0.5% solution 
of polyisobutylmethacrylate (Plexigum P 28, Röhm and Haas, Darmstadt, Germany) in n-hexane-chloroform 
(9:1). After blocking with BSA-PBSt (1% bovine serum albumin in phosphate buffered saline containing 0.05% 
Tween 20) for 1 h, plates were incubated overnight with BSA-PBSt diluted serum (1/20) and washed thoroughly 
with PBSt. Binding was detected following 2  h incubation with BSA-PBSt diluted (1/1,000) peroxidase-con-
jugated anti-human IgM (μ chain) or IgG (γ chain) goat antibodies (Sigma, USA). For IgG subclass determi-
nation, BSA-PBSt diluted biotin-conjugated antibodies against human γ1 (IgG1), γ2 (IgG2), γ3 (IgG3) o γ4 
(IgG4) chains (Sigma, USA) were incubated for 2 h, followed by 1 h incubation with PBSt-diluted peroxidase-
conjugated streptavidin (Sigma, USA). All the incubation steps were performed at 4 °C. After washing, color 
development was achieved in a substrate solution containing 2.8 mM 4-chloro-1-naphtol and 0.01%  H2O2 in 
methanol-20 mM Tris–HCl buffer, pH 7.4 (1:29). Plates were finally washed with PBSt after 20 min to stop the 
reaction. Digital images of immunostaining results were quantified using ImageJ software (1.52 version) and 
converted to categorical data upon setting a minimal peak area threshold of 500.
Statistical analyses. Antibody reactivity reported as categorical data was combined into groups for statis-
tical purposes. Immunostaining against non-self glycans (GA1, Forssman, Nt7 and blood group "A" glycosphin-
golipid for “0” and “B” blood group individuals) was grouped as “non-self glycan” reactivity. IgM populations 
against GM1, GD1b and GM2 are present in normal human  sera6; hence, IgG reactivity against GM1, GD1b 
and GM2 was at times considered a subgroup (“self glycan A”). Finally, IgG response against GM3, GD3, GD1a, 
GT1b and GQ1b was counted as another subgroup of self glycans (“self glycan B”). For each given antigen group, 
IgG subclass distribution analyses were done by comparing the number of samples positive for each IgG subclass 
to the number of samples positive for total IgG antibodies towards that antigen (considered as the total sample 
number). Data were examined by Fisher’s exact test with Prism 6 (GraphPad software, La Jolla, CA). Differences 
with P value < 0.05 were considered significant. Degrees of statistical significance are presented as follows: *, 
p < 0.05; **, p < 0.01; ***, p < 0.001, or ****, p < 0.0001.
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